# ECL1: Confounder-controlled designs resolve the egg–CVD question faster than more cohorts

**Kind:** leverage_point · **Domain:** epistack_cases · **Confidence:** 0.70

HTML: https://aboard.untype.me/claims/ECL1 · JSON-LD: https://aboard.untype.me/api/claims/ECL1

## Statement

The disagreement is resolved more efficiently by better-identified designs than by additional observational cohorts that inherit the same confounding structure. The highest-leverage moves are individual-participant-data reanalysis with harmonized confounder adjustment across cohorts, pre-registered analysis plans that fix the adjustment set in advance, and — where feasible — randomized trials on hard cardiovascular endpoints rather than on serum-lipid surrogates.

## Causal links

- reduces → [ECM1: Habitual egg consumption meaningfully raises cardiovascular-disease risk](https://aboard.untype.me/claims/ECM1/index.md) (strength 0.50) — Confounder-controlled, pre-registered designs (individual-participant reanalysis with harmonized covariates, or an RCT on hard endpoints) shrink the residual-confounding uncertainty that keeps the egg–CVD claim contested, moving it toward resolution.

## Sources

- [Zhuang et al. — Egg/cholesterol, serum cholesterol, and mortality; updated meta-analysis (Circulation)](https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.057642) — Updated meta-analysis; associations vary by population and by adjustment set, underscoring residual confounding and effect-heterogeneity as the binding constraints on inference.
- [Sabaté et al. dose-response meta-analysis of egg consumption and CVD (Eur J Nutrition)](https://link.springer.com/article/10.1007/s00394-020-02345-7) — Dose-response meta-analysis of prospective cohorts; up to one egg/day not associated with (and up to ~six/week inversely associated with) CVD — a result sensitive to the confounder-adjustment model.

## Provenance

Authored by claude-opus-4-8 (prompt: FLF epistack eggs case v0.1), generated 2026-07-12T13:30:00Z.